Urgent

Pulmonary arterial hypertension (PAH) — chronic management

Pulmonary circulation · Cardiac
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Group 1 pulmonary hypertension: precapillary PH (mean PAP >20 mmHg, PVR >2 WU, normal wedge) from pulmonary arteriopathy — idiopathic, heritable, connective-tissue-disease, drug/toxin, congenital heart disease or portopulmonary. Progressive RV failure. Requires expert-centre diagnosis and targeted vasodilator therapy; must be separated from the far commoner Groups 2 (left heart) and 3 (lung disease).

Red flags

  • Syncope or presyncope (ominous — poor RV reserve)
  • Rapidly worsening dyspnoea, rising NT-proBNP, falling 6MWD
  • Signs of decompensated RV failure (hypotension, rising JVP, ascites, oliguria)
  • Haemoptysis
  • Pregnancy in a PAH patient (very high mortality)
  • Systemic hypotension after starting a vasodilator

Assessment

Differential diagnosis

  • Group 2 PH — left heart disease (HFpEF/HFrEF, valve disease) — commonest
  • Group 3 PH — lung disease/hypoxia (COPD, ILD)
  • Group 4 PH — chronic thromboembolic PH (CTEPH)
  • Group 5 PH — multifactorial
  • RV failure of other cause
  • Deconditioning / anaemia causing breathlessness

Investigations

  • Right heart catheterisation — CONFIRMS diagnosis: mean PAP >20 mmHg, PCWP <=15 mmHg, PVR >2 Wood units; vasoreactivity testing in idiopathic/heritable/drug-induced
  • Echocardiogram — estimated PASP, RV size/function, exclude left heart/valve disease
  • V/Q scan — mandatory to exclude CTEPH (Group 4)
  • PFTs + DLCO, high-resolution CT chest (lung disease), ABG/overnight oximetry
  • Bloods: connective tissue screen (ANA/ENA, scleroderma antibodies), HIV, LFTs (portopulmonary), NT-proBNP (prognosis), TFTs
  • 6-minute walk test and risk stratification (ESC/ERS risk tables)

Management

  • Refer to a specialist PH centre — do NOT start PAH-specific drugs on echo alone; confirm by right heart catheter and classify the group
  • Exclude Group 2/3/4 causes (echo, PFTs/CT, mandatory V/Q for CTEPH)
  • Perform acute vasoreactivity testing in idiopathic/heritable/drug PAH — responders may trial high-dose calcium channel blockers
  • Risk-stratify (low/intermediate/high) and start combination targeted therapy (usually dual oral up-front: ERA + PDE5i) in most; escalate to triple incl. parenteral prostacyclin in high-risk
  • Add general measures: supervised rehab, diuretics for RV failure, oxygen if hypoxic, anticoagulation selectively (e.g. not routine in idiopathic), contraception counselling (pregnancy high-risk)
  • Reassess at 3-6 months against risk goals; escalate therapy if not low-risk; refer for lung transplantation if progressive despite therapy

Drugs & doses

Endothelin receptor antagonist: ambrisentan 5-10 mg PO once daily OR macitentan 10 mg PO once daily OR bosentan 62.5-125 mg PO BD (LFT monitoring; teratogenic) [verify]
PDE5 inhibitor: sildenafil 20 mg PO TDS OR tadalafil 20-40 mg PO once daily
sGC stimulator: riociguat 1 mg PO TDS, titrate to max 2.5 mg TDS (do NOT combine with PDE5i) — option for PAH and CTEPH
Prostacyclin pathway: epoprostenol IV infusion (high-risk; continuous, specialist) / treprostinil SC-IV-inhaled / selexipag 200 mcg PO BD titrated (oral IP-receptor agonist)
Sotatercept SC (activin-signalling inhibitor) — add-on in intermediate/high-risk per recent updates (STELLAR) [verify local approval/dose]
Calcium channel blocker (e.g. amlodipine/nifedipine high dose) ONLY for confirmed acute vasoreactivity responders [specialist]
Furosemide 20-40 mg PO/IV for RV failure/congestion; oxygen if SpO2 <90%; spironolactone for fluid overload
AVOID non-selective vasodilators, pregnancy, and decongestant sympathomimetics; cautious with anaesthesia/sedation (RV sensitive)

Disposition

Manage through a designated PH specialist centre; admit RV decompensation/syncope to high-dependency care. Escalate therapy against risk goals; consider transplant referral for refractory disease.

Complications & pitfalls

  • Progressive right ventricular failure and death
  • Arrhythmia (atrial flutter/fibrillation — poorly tolerated)
  • Syncope / sudden death
  • Haemoptysis
  • Decompensation with intercurrent illness, surgery or pregnancy

Exam pearls

  • PAH is a diagnosis of exclusion confirmed by right heart catheter — most 'PH on echo' is Group 2 (left heart) or Group 3 (lung), which are managed by treating the underlying disease, NOT PAH drugs.
  • A V/Q scan is mandatory to exclude CTEPH (Group 4), which may be cured by pulmonary endarterectomy or treated with riociguat/balloon angioplasty.
  • 2022 ESC/ERS guidance favours up-front combination therapy and risk-based escalation; sotatercept (STELLAR) has been added to recent ERS updates as add-on therapy.
  • Pregnancy carries very high maternal mortality in PAH — ensure effective contraception and pre-pregnancy counselling.
  • Do not acutely crash the systemic BP: the failing RV is preload- and afterload-sensitive; in RV failure avoid aggressive vasodilatation and manage in expert hands.

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.